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Abstract
Analyses of NY-ESO-1-specific spontaneous immune responses in cancer patients revealed that antibody and both CD4
+ and
CD8
+ T cell responses were induced together in cancer patients. To explore whether such integrated immune responses are
also spontaneously induced for other tumor antigens, we have evaluated antibody and T cell responses against self/tumor
antigen p53 in ovarian cancer patients and healthy individuals. We found that 21% (64/298) of ovarian cancer patients but
no healthy donors showed specific IgG responses against wild-type p53 protein. While none of 12 patients with high titer
p53 antibody showed spontaneous p53-specific CD8
+ T cell responses following a single in vitro sensitization, significant
p53-specific IFN-c producing CD4
+ T cells were detected in 6 patients. Surprisingly, similar levels of p53-specific CD4
+ T cells
but not CD8
+ T cells were also detected in 5/10 seronegative cancer patients and 9/12 healthy donors. Importantly, p53-
specific CD4
+ T cells in healthy donors originated from a CD45RA
2 antigen-experienced T cell population and recognized
naturally processed wild-type p53 protein. These results raise the possibility that p53-specific CD4
+ T cells reflect
abnormalities in p53 occurring in normal individuals and that they may play a role in processes of immunosurveillance or
immunoregulation of p53-related neoplastic events.
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Introduction
Increasing evidence shows that both tumor antigen-specific
CD4
+ and CD8
+ T cells play a critical role in eradicating cancer
[1,2]. We have extensively investigated spontaneous or vaccine-
induced immune responses against cancer-testis antigen NY-ESO-
1 as a prototype tumor antigen in human [3,4,5,6,7,8]. Naturally
occurring NY-ESO-1-specific CD4
+ and CD8
+ T cell responses
were typically detected only in patients who had serum antibody
against NY-ESO-1, indicating that spontaneous immune respons-
es against NY-ESO-1 in cancer patients with NY-ESO-1
expressing tumors were highly integrated [3,4]. Recently, it was
shown that after vaccination with NY-ESO-1 protein and CpG,
NY-ESO-1-specific CD4
+ T cells became detectable first, followed
by the appearance of antibody and CD8
+ T cells, suggesting a role
for NY-ESO-1-specific CD4
+ T cells in facilitating antibody and
CD8
+ T cell responses after immunotherapy [8]. In addition, we
recently found that vaccination with MAGE-A3 protein induced
integrated MAGE-A3-specific antibody, CD8
+ and CD4
+ T cell
responses [9]. In non-small cell lung cancer patients who received
MAGE-A3 protein formulated in the adjuvant system AS02B,
CD8
+ T cell responses were induced only in patients who
developed very high titer antibody and strong CD4
+ T cell
responses. However, such correlation between antibody and T cell
responses has not been fully addressed for other human tumor
antigens.
Over the past decades, immune responses against p53 have
been extensively investigated [10,11,12,13]. The p53 protein was
discovered in our laboratory as an immunogenic tumor-specific
antigen by serological investigation of tumor-bearing mice [14],
and concomitantly in two other laboratories using other methods
[15,16]. It was later discovered that the p53 gene is frequently
mutated in various cancers, leading to loss of heterozygoty,
dysregulation of p53 feedback networks, and ultimately resulting in
slower p53 turnover and thus accumulation of mutant p53 protein
in tumor cells. In humans, p53 is accumulated in up to 70% of
tumors from patients with certain cancers such as colon or head
and neck cancer, and this accumulation is a highly immunogenic
event, spontaneously triggering high-titered specific antibody
responses [12]. Indeed, p53 has been one of the most frequently
detected antigens recognized by naturally occurring antibodies in
cancer patients by the screening of cDNA expression libraries
derived from human tumors with autologous antibody (SEREX)
and by ELISA in our laboratory [17,18,19,20]. Naturally
occurring p53 serum antibodies in cancer patients are known to
recognize the wild-type N-terminus or C-terminus sequences of
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mutations occur. We and others have also investigated T cell
responses against wild-type p53 and many epitopes for both CD8
+
and CD4
+ T cell have been determined by reverse immunology
approaches and repeated stimulation of T cells with synthesized
peptides [10,21,22]. Recent results of T cell immunomonitoring of
ovarian and colorectal cancer patients vaccinated with p53
overlapping peptides showed strong induction of p53-specific
CD4
+ T cell responses, that were even detectable by ex vivo
analyses of peripheral blood mononuclear cells (PBMCs) after
vaccination without inducing any detectable p53-specific CD8
+ T
cells [23,24].
In the present study, we have investigated spontaneous antibody
and T cell responses against p53 in ovarian cancer patients, whose
tumors frequently accumulate p53 protein [25], and healthy donors.
To compare the in vivo immunogenicity of p53 with that of NY-ESO-
1, we monitored p53-specific CD4
+ and CD8
+ T cell responses using
the immunomonitoring procedures that were developed to monitor
spontaneous NY-ESO-1-specific T cell responses. These standard-
ized methods were previously shown to detect NY-ESO-1-specific
circulating CD4
+ and CD8
+ T cell responses only in NY-ESO-1-
seropositive patients with NY-ESO-1-expressing tumor, but not in
healthy donors with low frequency of precursors [4,26]. Using this
protocol, we found that IFN-c-producing CD4
+ Tc e l l sa g a i n s tw i l d -
type p53 sequences were detected frequently in seropositive cancer
patients. Surprisingly, spontaneous p53-specific CD4
+ Tc e l l
responses of similar magnitude were also found in most seronegative
patients and healthy donors. In contrast, no spontaneous CD8
+ Tce ll
responses against wild-type p53 nor againstthe patients’ own mutated
p53 sequenceswere detected in any donorstested, which suggests that
the spontaneous activation of CD8
+ T cell responses against p53 is
strongly controlled in vivo.
Materials and Methods
Patients and healthy donors’ samples
PBMCs and serum were obtained from ovarian cancer patients
at the Roswell Park Cancer Institute, under an approved protocol
from the Institutional Review Board. Written informed consent
was obtained from all patients. PBMCs and serum from healthy
donors were obtained from New York Blood Center.
Measurement of serum p53-specific antibody
Recombinant wild-type p53 was produced and p53-specific
serum antibody level was measured as described previously [20]. A
reciprocal titer was estimated from optical density readings of
serially diluted samples and controls as described [20].
Overlapping peptides
Sequences of overlapping peptides from wild-type p53 protein
used for presensitization and detection are shown in Table S1. All
peptides were synthesized by Biosynthesis (Lewisville, TX) and were
dissolved in dimethyl sulfoxide (DMSO) at 10 mM concentration
and stored at 280uC. They were designed to be 25 amino acid
length except #1 (19-mer) and #30 (22-mer) and have 15 amino
acid overlaps. Amino acid for codon 72 of wild-type p53 frequently
shows Arg to Pro polymorphism [27]. To deal with this
polymorphism, two different peptides with Arg or Pro at position
72 were prepared for peptide #6 and were mixed at a 1:1 ratio.
Presensitization
In vitro presensitization was performed as described before [28].
CD8
+ and CD4
+ T cells were separated from PBMCs by using
Dynabeads (Invitrogen-Dynal AS) and were independently
stimulated with CD8
2CD4
2 cells that were pulsed overnight
with 1 pool (#1–#30), 2 pools (#1–#15 and #16–#30), or 3
pools (#1–#10, #11–#20, and #21–#30) of overlapping
peptides according to the number of cells after separation and
irradiated. Cell cultures were supplemented with 10 U/ml IL-2
and 20 ng/ml IL-7 twice a week. In parallel, a portion of CD4
+ T
cells was polyclonally expanded with phytohaemagglutinin (PHA,
Remel) in the presence of low dose IL-2 and IL-7, to be used as
target cells (T-APC) in ELISPOT assay. In some experiments,
CD4
+ T cells were further separated into CD45RA
+ and
CD45RA
2 subsets by phycoerythrin (PE)-conjugated anti-CD
45RA monoclonal antibody (mAb) (BD Biosciences) and anti-PE-
magnetic beads (Miltenyi Biotec).
Detection of p53-specific T cell response
p53-specific IFN-c production was evaluated by ELISPOT
assay at day 9–12 for CD8
+ T cells and day 18–25 for CD4
+ T
cells. First, T cells were evaluated for their reactivity against 6
pools of 5 peptides (#1–#5, #6–#10, etc.). In some experiments,
a pool of 17 overlapping peptides from NY-ESO-1 was used as
irrelevant peptides. If IFN-c production was detected against any
of peptide pools, independent peptides in the pool were tested to
determine a single peptide recognized. All results from ELISPOT
assays were presented as the average number of IFN-c spot
forming cells from duplicate wells without subtracting the number
of background spots against unpulsed target cells. Responses were
considered positive if the number of spots against peptide(s)-pulsed
target cells was 3 times more than that against unpulsed target cells
and more than 25 spots/50,000 effector T cells. For some patients,
p53-specific T cells were detected by intracellular cytokine staining
and CD107a expression assays. Intracellular cytokine staining for
IFN-c, IL-4, and TNF-a was performed as described previously
[28]. For CD107a expression assays, presensitized CD8
+ T cells
were restimulated in the presence of 40 ml/ml PE-conjugated anti-
CD107a mAb (BD Biosciences) and 0.66 ml/ml GolgiStop (BD
Biosciences). In some experiments, p53 peptide-specific CD4
+ T
cells were isolated by flow-cytometric sorting of CD154 expressing
cells after restimulation with p53 peptides and they were
polyclonally expanded with PHA as described previously [28].
Recognition of naturally-processed p53 protein and cytokine
production by p53-specific CD4
+ T cell lines were investigated by
using autologous monocyte-derived dendritic cells (mo-DCs) pre-
pulsed overnight with p53 overlapping peptides (3.3 mM),
recombinant p53 protein (20 mg/ml) or control NY-ESO-1
protein (20 mg/ml). Cytokine levels in the supernatants were
measured by sandwich ELISA using the following mAb pairs:
unlabelled and biotinylated-anti-IFN-c (BD Biosciences), unla-
belled and biotinylated-anti-GM-CSF mAbs (BD Biosciences),
unlabelled and biotinylated-anti-IL-4 mAbs (BD Biosciences),
unlabelled and biotinylated-anti-IL-13 mAbs (eBioscience), unla-
belled and biotinylated-anti-IL-10 mAbs (eBioscience), unlabelled
and biotinylated-anti-TGF-b mAbs (eBioscience), unlabelled and
biotinylated-anti-IL-17 mAbs (eBioscience), and unlabelled and
biotinylated-anti-IL-9 mAbs (eBioscience). Standard cytokine
proteins were obtained from eBioscience.
Results
Anti-p53 antibody response
To evaluate spontaneous immunity against p53, we measured
serum antibody titers against p53 and NY-ESO-1 proteins in 298
advanced epithelial ovarian cancer patients and 153 healthy
individuals by ELISA. As shown in Figure 1, 21% of patients but
none of the healthy individuals showed significant anti-p53 serum
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ESO-1 antibody responses observed (21%). These frequencies of
spontaneous antibody responses against p53 and NY-ESO-1 are in
the range of those reported for ovarian cancer patients in various
studies [29]. In contrast, a smaller number of patients (7%) showed
significant serum antibody against cancer/testis antigen MAGE-
A3 (data not shown). The frequency of patients who showed both
NY-ESO-1 and p53 serum antibodies was 4.7%, which is close to
the calculated frequency from frequencies against each antigen
assuming that the induction of these responses is independent (0.21
(21% against p53)60.21 (21% against NY-ESO-1)=0.044 (4.4%
against both antigens)).
Undetectable spontaneous CD8
+ T cell response in
cancer patients and healthy donors
For the immunomonitoring of spontaneous T cell responses, it is
important to select a method that can distinguish in vivo-primed T
cells from in vitro-induced T cells. To monitor spontaneously-
induced T cell responses against p53, we employed a single in vitro
sensitization protocol that has been developed and validated to
detect spontaneous NY-ESO-1-specific T cell responses only in
NY-ESO-1 seropositive cancer patients but not in healthy
individuals. Using this protocol, NY-ESO-1-specific CD8
+ T cells
were frequently detected from NY-ESO-1 seropositive ovarian
cancer patients but not from healthy individuals in this study
cohort (Figure S1(A)). In contrast, multiple rounds of stimulation
by professional antigen processing cells (APCs) such as mo-DCs
can induce NY-ESO-1-specific T cells from naive NY-ESO-1-
specific precursors in healthy donors [30,31]. Because of the
frequent occurrence of spontaneous serum antibody against p53 in
ovarian cancer patients, we first analyzed p53-specific CD8
+ T cell
responses in these patients. From the finding that spontaneous
NY-ESO-1-specific T cells are detectable only in seropositive
patients, 12 ovarian cancer patients with spontaneous antibody
responses against p53 were selected for the evaluation of T cell
responses. CD8
+ and CD4
+ T cells were isolated from PBMCs as
described in materials and methods, and they were separately
stimulated with p53 peptide-pulsed CD4
2CD8
2 cells. After
culturing for about 10 days, the number of IFN-c-producing
p53-specific CD8
+ T cells was evaluated by ELISPOT assay. As
shown in Figure 2A, two representative seropositive patients
showed no detectable anti-p53 CD8
+ T cell response by our
standard immunomonitoring protocol. Similarly, no significant
IFN-c production from CD8
+ T cells was detected from 10
additional seropositive patients (Figure 2B). Ten seronegative
ovarian cancer patients and 12 healthy donors were also tested for
their spontaneous CD8
+ T cell response against p53 and as
expected, there was no indication of p53-specific CD8
+ T cells
(Figure 2B). It is possible that p53-specific CD8
+ T cells lack IFN-
c-producing ability and that they are detectable by the expression
of other molecules. To test if p53-specific CD8
+ T cells were
detectable by other activation-induced molecules, 5 seropositive
and 5 seronegative patients were analyzed for TNF-a production
and CD107a expression after restimulation with peptides. As
shown in Figure 2C, no p53-specific CD8
+ T cell response was
detected based on TNF-a and CD107a expression.
These results indicate that spontaneous IFN-c-producing CD8
+
T cell responses against wild-type p53 were not detectable even in
seropositive cancer patients by our presensitization protocol in
contrast to the frequent detection of NY-ESO-1-specific CD8
+ T
cell responses in NY-ESO-1-seropositive patients (Figure S1(A)).
Accumulation of mutated p53 protein in tumor cells is known to
correlate with antibody response [32]. Because mutated peptides
are considered to be immunogenic due to absence of tolerance and
immunogenicity of mutant p53 to induce CD8
+ T cell responses
was demonstrated in mice [33,34], we next sought CD8
+ T cell
responses against mutated p53. To do this, exons 5–7 of the p53
gene from tumor tissues and normal lymphocytes of ovarian
cancer patients were sequenced to identify potential p53 mutations
in the tumor (data not shown). Among the mutations detected,
three frequently occurring mutations, S127F, R273C, and
R282W, were selected to look for specific CD8
+ T cell response
against epitopes encompassing these mutations. CD8
+ T cells from
three patients who had tumor with S127F, R273C or R282W
mutation were stimulated with peptides containing the patient’s
p53 mutation or with peptides containing the corresponding wild-
type sequence. No mutated peptide-specific CD8
+ T cell response
was detected in these three patients (data not shown).
CD4
+ T cell responses in cancer patients and healthy
individuals
To detect naturally occurring CD4
+ T cell responses against
p53, CD4
+ T cells from seropositive cancer patients were
stimulated with overlapping peptides pulsed on autologous T
cell-depleted PBMCs used as APCs. After 20 days of culture in the
presence of low-dose IL-2 and IL-7, IFN-c-producing CD4
+ T
cells were enumerated by ELISPOT assay against subpools of
overlapping peptides and then against individual peptides from
reactive subpools. In contrast to the undetectable p53-specific
CD8
+ T cells, significant IFN-c-producing p53-specific CD4
+ T
cell responses to subpools of overlapping peptides were found in 6
out of 12 seropositive patients (Figure 3A and data not shown),
with comparable magnitude to spontaneous CD4
+ T cell responses
against NY-ESO-1 in NY-ESO-1 seropositive ovarian cancer
patients in this study cohort (Figure S1(B)). We next evaluated
spontaneous CD4
+ T cell responses against p53 in 10 seronegative
Figure 1. Spontaneous antibody responses in ovarian cancer
patients. Sera from 298 ovarian cancer patients and 153 healthy
individuals were evaluated for the antibody against wild-type p53 and
NY-ESO-1 proteins by ELISA. Reciprocal titers are calculated as described
in the reference [20].
doi:10.1371/journal.pone.0023651.g001
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presensitization method did not detect NY-ESO-1-specific CD4
+
T cells in healthy individuals (Figure S1(B)), the same procedure
detected significant IFN-c-producing CD4
+ T cell responses in 5/
10 seronegative patients and 9/12 healthy individuals tested
(Figures 3B and C and data not shown). In selected patients, p53-
specific CD4
+ T cells were detectable by TNF-a production
following intracellular cytokine staining (Figure S2).
Figure 4 summarizes epitopes recognized by CD4
+ T cells from
seropositive and seronegative cancer patients and healthy donors.
Figure 2. Undetectable p53-specific CD8
+ T cells in ovarian cancer patients and healthy donors. (A) CD8
+ T cells from antibody positive
ovarian cancer patients were presensitized with a pool of 30 p53 overlapping peptides. After 9–12 days, p53-specific IFN-c producing T cells were
evaluated by ELISPOT assays. Error bars represent standard deviation (SD) of duplicate wells. Autologous T-APCs were used as target cells in ELISPOT
assays. (B) CD8
+ T cell responses in 7 seropositive and 5 seronegative ovarian cancer patients and 12 healthy donors are shown. (C) Presensitized
CD8
+ T cells were analyzed by intracellular TNF-a staining and CD107a expression assays after restimulation with p53-peptides-pulsed, irrelevant (NY-
ESO-1) peptides-pulsed or unpulsed target cells.
doi:10.1371/journal.pone.0023651.g002
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seronegative cancer patients and healthy donors were distributed
over the entire sequence of the p53 protein. Certain peptides such
as #9, #13 and #26 induced more frequent CD4
+ T cell
responses in 4 (20% of responders), 6 (30%) and 7 (35%) donors,
respectively. Some seronegative cancer patients and healthy
donors showed multiple epitope-specific CD4
+ T cell responses,
as seen in seropositive cancer patients. To consider the frequently
observed polymorphism at a codon 72, we used a mixture of two
variant peptides for peptide #6 (Table S1), that could induce de
novo responses in individuals with a p53 homozygous genotype at a
codon 72. However, no T cell response against #6 peptides was
detected in this study, indicating that our short-term culture
protocol did not appear to induce de novo CD4
+ T cell responses.
The magnitude of responses and distribution of epitopes were
similar in cancer patients and healthy individuals. It is well-known
that epitopes recognized by p53-specific antibody are limited to
the N-terminus and C-terminus region of the protein [32,35].
However, there was no correlation between the maps of epitopes
for CD4
+ T cells and for antibodies (Figure 4). In addition,
mutation of p53 protein in cancer cells is frequently found in the
central region of the gene [32]. However, there was no
overrepresentation of CD4
+ T cell epitopes in this region,
suggesting that the responses were not mediated by cross-reactivity
of mutated peptide-specific CD4
+ T cells. To find mutation-
specific CD4
+ T cells in three patients with mutated p53-
expressing tumor, CD4
+ T cells from the patients were
presensitized with peptides containing the patients’ cognate
mutation. Although one patient whose tumor had S127F mutation
showed weak CD4
+ T cell responses against both mutated and
corresponding wild-type peptides, no significant mutation-specific
CD4
+ T cell response could be detected (data not shown).
Origin of repertoire of p53-specific CD4
+ T cells
In contrast to the detection of p53-specific CD4+ T cells in
seropositive and seronegative cancer patients as well as in healthy
donors, our presensitization protocol only allows detection of NY-
ESO-1-specific IFN-c-producing CD4
+ T cells in NY-ESO-1
seropositive cancer patients but not in seronegative cancer patients
and healthy individuals when PBMC-derived whole CD4
+ T cells
are presensitized with NY-ESO-1 overlapping peptides. However,
we recently reported that NY-ESO-1-specific CD4
+ T cells could
be induced from CD45RA
+ naı ¨ve CD4
+ T cells in healthy donors
after in vitro presensitization by removing CD25
+ regulatory T cells
[36,37]. These results indicate that NY-ESO-1-specific CD4
+ T
cell precursors present in healthy individuals are susceptible to
suppression by regulatory T cells, but in cancer patients, in vivo-
primed NY-ESO-1-specific CD4
+ T cells become resistant to this
suppression [36,37]. Detection of IFN-c-secreting p53-specific
CD4
+ T cells in healthy individuals after a single in vitro
sensitization in the presence of regulatory T cells suggests that
they are already primed in vivo. To determine the activation status
of p53-specific CD4
+ T cells in healthy donors, naı ¨ve and antigen-
experienced CD4
+ T cells were separated based on CD45RA
expression and were stimulated with p53 overlapping peptides.
Induction of p53-specific CD4
+ T cells was evaluated by
ELISPOT assays. As shown in Figures 5A and 5B, in contrast to
what had been observed with NY-ESO-1-specific CD4
+ T cells,
p53-specific IFN-c-producing CD4
+ T cells were detectable from a
CD45RA
2 antigen-experienced population of healthy donors. In
addition, smaller responses were also induced from CD45RA
+
naı ¨ve T cell population (Figure 5A). Because CD45RA is not an
absolute marker for naı ¨ve T cells, there is still a possibility that
p53-specific CD4
+ T cells in the CD45RA
+ T cell population were
already activated in vivo [38]. However, this result indicated that at
least a part of p53-specific CD4
+ T cells have been primed in vivo
even in healthy individuals.
Characterization of p53-specific CD4
+ T cells
To further characterize p53-specific CD4
+ T cells in healthy
donors, p53-specific T cell lines were generated by isolating
CD154 expressing CD4
+ T cells after restimulation with p53
peptides followed by polyclonal expansion with PHA (data not
shown). This CD154 expression-based method was employed to
detect multiple CD4
+ T cell subsets for the analysis of cytokine
producing pattern [28]. Four CD4
+ T cell lines were generated
Figure 3. Detection of p53-specific CD4
+ T cells in ovarian
cancer patients and healthy donors. CD4
+ T cells from antibody
positive (A) and negative (B) ovarian cancer patients and healthy donors
(C) were presensitized with pool(s) of p53 overlapping peptides. After
18–25 days, p53-specific IFN-c producing T cells were evaluated against
peptide-pulsed or unpulsed (w) target cells by ELISPOT assays. Error bars
represent SD of duplicate wells. Autologous T-APCs were used as target
cells in ELISPOT assays. T cell responses were first evaluated against
subpools of peptides (1st assay) and then against independent peptide
in a reactive subpool (2nd assay). For the healthy donor shown in (C),
CD4
+ T cells that were presensitized with #1–#10 or #21–#30 peptide
did not show any significant responses (data not shown).
doi:10.1371/journal.pone.0023651.g003
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+ Tc e l l
lines specifically produced GM-CSF, which is produced from
both Th1 and Th2 cells, after stimulation with peptide-pulsed
mo-DCs (Table 1). Levels of other cytokines produced by CD4
+
T cell lines are shown in Table 1. Consistent with the efficient
detection of p53-specific CD4
+ T cells by IFN-c ELISPOT
assays, all p53-specific CD4
+ T cell lines from healthy donors
produced large amounts of IFN-c.I na d d i t i o nt oI F N - c,
significant levels of IL-13 and small amounts of IL-4 were also
specifically produced, indicating that the T cell lines were a
mixture of Th1 and Th2 cells. Two CD4
+ T cell lines produced
small levels of immunoregulatory cytokine, IL-10. One CD4
+ T
cell line produced small but significant levels of IL-9, which is
produced by Th9 and is regulated by IL-4 and TGF-b,
potentially indicating the presence of TGF-b signaling during
the differentiation of p53-specific CD4
+ T cells. However,
production of TGF-b was not detected in the supernatant (data
not shown). In addition, IL-17, which is produced by Th17, was
not detected in any CD4
+ T cell lines (data not shown). Next, the
recognition of naturally-processed p53 protein was investigated
by using autologous mo-DCs as APCs. As shown in Figure 5C, all
CD4
+ T cell lines efficiently recognized p53 protein-pulsed target
cells as detected by IFN-c secretion. This result demonstrates
p53-specific CD4
+ T cells detectable in healthy donors are able to
recognize naturally-processed p53 protein and makes it unlikely
that they are activated in vivo by other proteins with similar
sequences.
Discussion
Accumulation of mutated p53 protein in tumor is observed
frequently in many types of tumors and induces humoral immune
responses, demonstrating strong immunogenicity of p53 [12].
Thus, p53 has been considered a promising target for vaccination
against multiple types of cancer. Yet, we report here the failure to
detect in vivo-primed p53-specific CD8
+ T cell responses in cancer
patients with spontaneous antibodies to p53 as well as in p53-
seronegative patients and in healthy donors using our single in vitro
sensitization protocol. In contrast, the same protocol frequently
detected NY-ESO-1-specific CD8
+ T cells in NY-ESO-1-seropos-
itive cancer patients in the same study cohort, indicating that
natural immunogenicity to induce spontaneous CD8
+ T cell
responses may be different in p53 and NY-ESO-1 even in
seropositive patients for these antigens. It was reported that
although cyclin B1-specific CD8
+ T cells became detectable after a
single in vitro stimulation, p53-specific CD8
+ T cells against 6
HLA-A*02 binding short peptides could not be detected in 5
cyclin B1-reactive and 5 non-reactive patients using the same
method [39]. Our results expand their observations by monitoring
CD8
+ T cell responses to the whole region of the protein using
overlapping peptides and by including with immunomonitoring of
spontaneous antibody and CD4
+ T cell responses. Several vaccine
trials such as p53-transduced DCs or long overlapping peptides
have reported induction of T cell responses with limited clinical
benefit [23,24,40,41]. Immunogenicity of p53 in mice was
Figure 4. Distribution of CD4
+ T cell epitopes in ovarian cancer patients and healthy donors. The magnitude of CD4
+ T cell responses in
ovarian cancer patients with or without p53-specific serum antibody and healthy donors against p53 overlapping peptides is plotted. Each symbol
represents one individual. All responses shown were significant as compared to the number of background spots. 6/12 seropositive (pink symbols)
and 5/10 seronegative (blue symbols) ovarian cancer patients and 9/12 healthy individuals (black symbols) showed positive CD4
+ T cell responses
against p53 peptide-pulsed target cells compared with unpulsed target cells.
doi:10.1371/journal.pone.0023651.g004
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+ T
cells but not CD4
+ T cells are anergic in wild-type mice
[42,43,44]. In p53 knock-out mice, immunizing with p53 led to
specific CD8
+ T cells of higher avidity compared to wild-type mice
[42]. A study in human leukocyte antigen (HLA)-A*02 transgenic
mice demonstrated that unresponsiveness of HLA-A*02-restricted
CD8
+ T cells was limited to the epitopes that were homologous in
human and mice, indicating that the tolerance was induced by
murine p53 [42,44]. In contrast, CD4
+ T cell responses against
wild-type p53 were similarly induced and their avidities were
almost identical in wild-type and p53
2/2 mice [43]. The presence
of p53-specific CD8
+ T cell precursors in PBMCs of cancer
patients and healthy individuals was reported by several groups
and p53-specific CD8
+ T cells have been found to specifically
recognize tumor cells accumulating p53 [22,45,46,47]. However,
these tumor-reactive p53-specific CD8
+ T cells were obtained only
after in vitro priming and extensive stimulations, and most other
p53-specific CD8
+ T cells from the literature were found to have
low avidity [42,48]. In addition, it was recently shown that p53-
specific CD8
+ T cells detected by ex vivo analyses using tetramers
express apoptotic markers [49], suggesting that CD8
+ T cells may
fail to expand because of apoptosis following antigen presensitiza-
tion in our protocol. Wild-type p53 is a ubiquitously-expressed
protein but the wild-type p53 protein expression in normal tissue is
hardly detectable due to rapid degradation by a proteasome-
dependent pathway, which eventually causes antigen presentation
Figure 5. Characterization of p53-specific CD4
+ T cells in healthy individuals. (A–B) In vivo priming of p53-specific CD4
+ T cells in healthy
individuals. CD4
+CD45RA
+ naı ¨ve and CD4
+CD45RA
2 antigen-experienced T cells were isolated by flow cytometry and presensitized with p53
overlapping peptides. After 20 days, p53-specific IFN-c-producing T cells were evaluated by ELISPOT assays. Autologous T-APCs were used as APCs.
(C) Recognition of naturally-processed p53 protein. p53-specific CD4
+ T cell lines against p53 #1–#15 peptides pool or #16–#30 peptides pool were
established from 3 healthy donors as described in materials and methods. They were stimulated by autologous mo-DC pre-pulsed with p53 peptides,
p53 protein, or NY-ESO-1 protein. IFN-c production was evaluated by ELISPOT assays (left) and ELISA (right). Error bars represent SD of duplicate wells.
doi:10.1371/journal.pone.0023651.g005
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+ T cells
to p53-accumulating tumors was recently investigated, leading to
the observation that CD8
+ T cells transduced with high affinity
p53-specific T cell receptor gene could recognize not only p53-
accumulating tumors but also tumors expressing wild-type p53,
irrespective of the expression level of p53 protein, and normal cells
such as peripheral blood stem cells and dendritic cells [52].
Because antigen presentation by professional APCs like DCs in
non-inflammatory condition is known to induce tolerance, a
constitutive presentation of wild-type p53 by DCs could be
considered to induce tolerance of high-avidity p53-specific CD8
+
T cells [53]. In addition to central tolerance caused by thymic
APCs expressing p53 [42,44], peripheral tolerance induction by
p53-expressing APCs may explain our observation that in vivo-
primed p53-specific CD8
+ T cells are not detected even in p53
seropositive ovarian cancer patients. It has been reported that p53-
specific CD8
+ T cells exist at low frequency and that they become
detectable after multiple stimulations in vitro [22,46,54]. Although
spontaneous activation of p53-specific CD8
+ T cells is regulated, it
is possible that p53-based vaccination or blockade of immune-
regulating signals such as CTLA-4 or PD-1 may induce the
activation and expansion of p53-specific CD8
+ T cells.
In contrast to CD8
+ T cells, p53-specific CD4
+ T cells were
detectable in seropositive cancer patients (Figure 3A). Surprisingly,
IFN-c-producing CD4
+ T cells against p53 were frequently
detected also in seronegative cancer patients and even in healthy
donors (Figure 3B and C). Our observation supports the previous
finding that p53-specific CD4
+ T cells were detectable in
seronegative colorectal cancer patients [55]. The magnitude and
epitope-distribution of CD4
+ T cell responses were similar in
seropositive and seronegative patients and healthy individuals
(Figure 4). p53-specific CD4
+ T cells in healthy donors were of
high avidity, recognized naturally-processed p53 protein, and
predominantly produced IFN-c in addition to other Th2-related
and immunoregulatory cytokines (Figure 5C and Table 1). In
contrast, IFN-c-producing NY-ESO-1-specific CD4
+ T cells were
detectable after a single presensitization only in seropositive cancer
patients but not in seronegative patients and healthy donors. Still,
we have recently found that NY-ESO-1-specific CD4
+ T cells are
detectable in healthy donors when CD25
+ regulatory T cells are
removed from the culture during presensitization [37]. Further-
more, we also found that naı ¨ve MAGE-A3-specific CD4
+ T cells
in healthy individuals, which were detectable by CD154
expression, were not detectable by IFN-c ELISPOT assays [28].
The fact that p53-specific CD4
+ T cells in healthy donors were
detectable without the need for depletion of regulatory T cells and
they produced IFN-c after a single presensitization procedure
indicated that they were already primed to differentiate into Th1
cells in vivo. Indeed, we found that p53-specific CD4
+ T cells were
detectable after expansion from CD45RA
2 antigen-experienced
population. Although CD4
+CD45RA
+ cells also contained p53-
specific CD4
+ T cells (Figure 5A), they could be terminally-
differentiated effector cells which lack the expression of CCR7
[38]. Further separation of CD45RA
+ cells into CCR7
+ and
CCR7
2 subsets is required to analyze the phenotypic distribution
of p53-specific CD4
+ T cells in healthy donors. The fact that p53-
specific CD4
+ T cells were frequently observed in healthy donors
and both seropositive and seronegative cancer patients in contrast
to CD8
+ T cells suggested that central and/or peripheral tolerance
against CD4
+ T cells is weak or absent, as indicated by studies in
mice [43]. The basis for the induction of in vivo priming of wild-
type p53-specific CD4
+ T cells in healthy individuals has not been
clarified from the present study. In addition to accumulation of
mutated p53 in malignant cells, wild-type p53 can also accumulate
in cells in response to cellular stresses such as UV irradiation and
nitric oxide and eventually causes cell cycle arrest and cell death
by apoptosis [56,57]. The release of wild-type p53 protein in the
presence of inflammatory responses associated with cellular
stresses is a possible mechanism to induce p53-specific CD4
+ T
cells in healthy individuals, and it cannot be excluded that frequent
p53 mutations not leading to cancer occur in normal individuals.
Investigation of the correlation between the presence of p53-
specific CD4
+ T cells and age or risk of cancer development is
helpful to understand the mechanism to induce p53-specific CD4
+
T cell responses. Interestingly, the average age of ovarian cancer
patients who showed CD4
+ T cell responses against p53 was
significantly higher than that of patients without CD4
+ T cell
responses (66.963.0 (11 responders) vs. 53.863.7 (10 non-
responders), p=0.013), whereas there was no significant correla-
tion between the average ages of patients and the status of p53-
specific serum antibodies (63.963.2 (11 seropositives) vs. 57.164.4
(10 seronegatives), p=0.221). It is possible that p53-specific B cells
were also continuously primed in response to cellular stress-
induced p53 release although the response may not be detectable
by antibody production. The detection of antibody responses
against many tumor antigens is usually associated with clinically
evident tumors, although anti-p53 antibody has been found in
asbestosis patients before their diagnosis of cancer [58]. The
presence of spontaneously activated p53-specific CD4
+ T cells in
healthy individuals is likely to play an important role in rapid
induction of antibody responses after malignant transformation.
Similar phenomenon of CD8
+ T cell selective tolerance
induction in the presence of normal CD4
+ T cell and antibody
responses was observed in transgenic mice that express influenza
HA protein in the lung and to a lesser extent in the thymus [59].
The tolerance in CD8
+ T cells was strictly epitope-specific,
because these animals could mount normal CD8
+ T cell responses
against an influenza strain carrying a HA epitope with one amino
acid substitution from the transgenic HA. If the mechanism for
tolerance induction in p53-specific CD8
+ T cells is similar, it is
possible that CD8
+ T cell responses are raised against mutated
p53. We previously demonstrated that one of three mutated p53
sequences that naturally occur in Meth A sarcoma induced CD8
+
T cell responses in mice [33,34]. To test this possibility, we
attempted to detect mutated peptide-specific CD8
+ T cells from
three patients whose tumor expressed relatively common muta-
tions (S127F, R273C or R282W) by stimulating with the peptide
harboring the patient’s own mutation. However, no CD8
+ T cell
Table 1. Cytokine levels (ng/ml) in supernatant of isolated
and expanded p53-specific CD4
+ T cell lines of healthy donors.
IFN-c GM-CSF IL-4 IL-13 IL-10 IL-9
HD4(#16–#30) 60.1(0.6) 8.5(0.2) 0.2(0.0) 4.9(0.1) 0.9(0.0) 0.0(0.0)
HD5(#1–#15) 44.4(0.5) 8.7(0.1) 0.2(0.0) 5.0(0.1) 0.1(0.0) 0.0(0.0)
HD6(#1–#15) 59.4(0.3) 10.9(0.1) 0.7(0.0) 5.4(0.1) 0.1(0.0) 0.1(0.0)
HD6(#16–#30) 66.5(0.1) 13.4(0.1) 0.4(0.0) 3.8(0.0) 0.8(0.0) 0.0(0.0)
CD4
+ T cell lines were obtained from healthy donors by isolating CD154
expressing cells after restimulation with #1–#15 or #16–#30 peptides pool
and expanding with PHA. p53-specific CD4
+ T cell lines (50,000 cells) and
peptide-pulsed autologous mo-DCs (50,000 cells) were cocultured for 20 hours
and cytokines levels in the supernatant were measured by ELISA. Numbers in
parentheses indicate background cytokine production against unpulsed
autologous mo-DCs. Cytokine production exceeding the limit of detection and
5 times higher than background production was considered to be significant
and is shown in bold.
doi:10.1371/journal.pone.0023651.t001
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shown). Because mutated p53 epitopes must have HLA anchoring
motifs for the induction of CD8
+ T cell responses, more patients
must be evaluated to demonstrate the presence or absence of
mutated p53-specific CD8
+ T cells and their spontaneous
activation in cancer patients. However, it is possible that mutated
peptide-specific CD8
+ T cells are cross-reactive to a corresponding
wild-type peptide and also deleted or rendered tolerant by wild-
type p53 presented by thymic epithelial cells or peripheral cells like
immature DCs.
In summary, this study revealed the strong immunogenicity of
p53 in inducing antibody and CD4
+ T cell responses without
inducing CD8
+ T cell responses. As already revealed from vaccine
trials using long overlapping peptides, vaccination with p53 is not
expected to induce effective p53-specific CTL responses. In
addition, because p53 is an intracellular protein and thus, p53-
specific antibody and CD4
+ T cells are not thought to directly
recognize tumor cells by classical antigen presentation pathways,
the role of these immune responses in the prevention of cancer is
still uncertain. In our preliminary analysis, the presence of anti-
p53 CD4
+ T cells in ovarian cancer patients did not correlate with
patients’ survival (data not shown), although the number of
patients in the analysis is too small to conclude. However, strong
immunogenicity of wild-type p53 to induce CD4
+ T cells
suggested that p53 could be utilized as helper epitopes in
multivalent cancer vaccine [23]. Although, both NY-ESO-1 and
p53 exhibit spontaneous humoral and CD4
+ T cell immune
responses in cancer patients who have antigen-expressing tumors,
CD8
+ T cell responses are undetectable against p53 in contrast to
a strong induction of CD8
+ T cell responses against NY-ESO-1
[3]. From our previous analyses of spontaneous immune responses
in cancer patients and healthy individuals, it was found that CD8
+
T cell responses against MAGE-A3 and NY-CO-58 was restricted
compared to NY-ESO-1 (Table S2). In contrast, spontaneous
CD4
+ T cell responses to MAGE-A3 were detected only in
seropositive cancer patients but those to NY-CO-58 could be
detected even in healthy individuals [9,28,60]. Many tumor-
related antigens have been discovered and their immunogenicity is
being evaluated in relation to their potential target for immuno-
therapy of cancer [61]. The induction of tumor antigen-specific
high avidity CD8
+ T cells that can efficiently destroy antigen-
expressing tumor cells is considered to be critical for successful
cancer vaccination. Because both antigen-specific CD4
+ T cells
and antigen-opsonizing antibodies are considered to help in
inducing antigen-specific CD8
+ T cells, each antigen must be
evaluated for their antigenic property to induce an integrated
immune response or split tolerance.
Supporting Information
Figure S1 Spontaneous T cell responses against NY-ESO-1 in
seropositive ovarian cancer patients and healthy donors. CD8
+ (A)
and CD4
+ (B) T cells from NY-ESO-1 seropositive ovarian cancer
patients and healthy individuals in the same study cohort of p53
immunomonitoring were presensitized with NY-ESO-1 overlap-
ping peptides and NY-ESO-1-specific T cells were evaluated by
ELISPOT assays using the same protocol used to monitor T cell
responses against p53.
(TIF)
Figure S2 Detection of p53-specific CD4
+ T cells by intracel-
lular cytokine staining. CD4
+ T cells from p53 seropositive and
seronegative ovarian cancer patients were presensitized with p53
overlapping peptides and p53-specific T cells were evaluated by
intracellular cytokine staining of TNF-a and IL-4. (A) Represen-
tative staining after co-culture with p53-peptides subpool-pulsed or
unpulsed target cells. (B) Summary of cytokine expressing cells in 4
seropositive and 4 seronegative patients.
(TIF)
Table S1 Numbering of overlapping peptides for wild-type p53.
(DOC)
Table S2 Spontaneous immune responses against tumor-related
antigens investigated in the New York Branch of Ludwig Institute
for Cancer Research.
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